Hematology · Medical Literature
Redefining Early Relapse in Multiple Myeloma — Time to Change the Rules
Abstract
New England Journal of Medicine, Volume 395, Issue 5, Page 506-507, July 30, 2026.
Clinical relevance
In patients with relapsed or refractory multiple myeloma who have received 1–3 prior lines of therapy including an anti-CD38 monoclonal antibody and lenalidomide, does teclistamab monotherapy improve progression-free and overall survival compared with investigator's choice of PVd or Kd? __SNAPSHOT__ {"studyDesign":"Phase 3, randomized, open-label, multicenter controlled trial (MajesTEC-9; NCT05572515); this submission is an editorial commentary by Mateos contextualizing the trial results","setting":"Global, multicenter; trial results simultaneously published in NEJM and presented at ASCO 2026","sampleSize":"n=593 (teclistamab: n=296; PVd/Kd: n=297)","population":"Adults with relapsed or refractory multiple myeloma (RRMM) after 1–3 prior lines of therapy, all previously exposed to an anti-CD38 monoclonal antibody and lenalidomide; prior BCMA-targeted therapy excluded; approximately 85% anti-CD38–refractory, 79% lenalidomide-refractory, and >90% refractory to last line of therapy; median age 70 years (range 34–86)","intervention":"Subcutaneous teclistamab (BCMA×CD3 bispecific T-cell engager antibody) monotherapy with step-up dosing; antimicrobial prophylaxis and immune globulin replacement recommended","comparator":"Investigator's choice of pomalidomide, bortezomib, and dexamethasone (PVd; 30.4% of control arm) or carfilzomib and dexamethasone (Kd; 69.6% of control arm)","primaryOutcome":"Progression-free survival (PFS) as assessed by an independent review committee (IRC)","followUp":"Median follow-up 17.3 months (interim analysis)","fundingSource":"Industry (Johnson & Johnson)"}
Key findings
At the pre-specified interim analysis (median follow-up 17.3 months), teclistamab met the primary endpoint with a statistically significant and clinically large reduction in the risk of disease progression or death versus PVd/Kd (HR 0.29; 95% CI 0.23–0.38; p<0.0001), representing a 71% relative risk reduction. Median PFS was not reached with teclistamab versus 8.2 months with PVd/Kd. The 18-month PFS rates were 69.8% versus 26.9%, an absolute difference of 42.9 percentage points (calculated). Overall survival also significantly favored teclistamab (HR 0.60; 95% CI 0.43–0.83; p=0.002), a 40% reduction in the risk of death; median OS was not reached in either arm, and estimated 18-month OS rates were 79.2% versus 68.6% (absolute difference 10.6 percentage points, calculated). All key secondary endpoints showed significant improvement: overall response rate (ORR) 84.5% vs 54.2%; complete response or better (≥CR) 65.9% vs 16.8% (OR 3.95; 95% CI 3.03–5.14; p<0.001); ≥VGPR 80.1% vs 36.4%. MRD-negative CR or better (ITT) was achieved by 38.5% vs 6.7% (OR 8.56; 95% CI 5.14–14.26). Median duration of response was not estimable with teclistamab versus 13.4 months with PVd/Kd; estimated 18-month DOR rate 80.6% vs 40.1%. PFS benefit was consistent across all prespecified subgroups, including lenalidomide-refractory (HR 0.30), anti-CD38–refractory (HR 0.32), high-risk cytogenetics (HR 0.27), and 1 vs 2–3 prior lines. NNT for 18-month PFS benefit: approximately 2.3 (calculated). Regarding safety: grade 3/4 treatment-emergent adverse events occurred in 84.9% (teclistamab) vs 76.3% (PVd/Kd); grade 5 events in 6.5% vs 3.5%. Cytokine release syndrome (CRS) occurred in 66.0% of teclistamab-treated patients, primarily grade 1–2; immune effector cell–associated neurotoxicity syndrome (ICANS) occurred in 4.1%. Grade 5 infections occurred in 5.5% of teclistamab-treated patients vs 2.8% with PVd/Kd, predominantly in patients with low IgG levels. Hypogammaglobulinemia was common in both arms (69.1% vs 50.2%).
Practice implications
IMPORTANT LIMITATION: Only the abstract of the Mateos editorial is available; the full editorial text, including her complete interpretive arguments and nuanced qualifications regarding the MajesTEC-9 trial findings, could not be reviewed. The following interpretation is based on publicly available MajesTEC-9 trial data (Touzeau et al., NEJM 2026) and contextual information, not on the editorial's proprietary analytical content. The MajesTEC-9 trial establishes that teclistamab monotherapy produces a statistically significant and clinically large improvement in both PFS and OS over PVd/Kd in anti-CD38– and lenalidomide-exposed RRMM patients after 1–3 prior lines — a population with historically poor outcomes and limited effective options. The OS benefit, observed despite substantial crossover to bispecific antibodies or CAR-T in the control arm, is particularly notable and strengthens the clinical validity of earlier BCMA-directed therapy deployment. Findings apply specifically to patients who have already received anti-CD38 and lenalidomide therapy and are BCMA-naïve; they do not directly address patients without prior anti-CD38 or lenalidomide exposure, transplant-eligible early relapse, or those who have already received BCMA-targeted agents. The editorial's title — 'Time to Change the Rules' — signals that Mateos views the MajesTEC-9 data as sufficient to redefine the treatment paradigm for early relapse in multiple myeloma, reflecting a conceptual shift from reserving bispecific antibodies as late salvage to deploying them at first or second relapse. Key unanswered questions include: optimal sequencing relative to CAR-T cell therapy, long-term (>17-month) durability, the benefit-risk ratio in community settings where step-up dosing infrastructure and infection monitoring capacity may be limited, and the management of the substantial infectious toxicity signal (particularly fatal infections and hypogammaglobulinemia). The open-label design precludes blinding, and industry sponsorship warrants independent confirmation, though the magnitude and consistency of benefit across subgroups reduce the likelihood that these are chance findings. __LIMITATIONS__ Only abstract of the Mateos editorial available; full editorial arguments and qualifications cannot be assessed.,Open-label design (no blinding of patients, investigators, or outcome assessors) introduces potential performance and detection bias.,Industry-funded by Johnson & Johnson; independent replication not yet available.,Interim analysis at median 17.3 months; median OS and median PFS for teclistamab not yet reached, so long-term durability remains uncertain.,Composite comparator (PVd or Kd) with Kd comprising ~70% of controls may not represent the optimal current standard of care in all regions; the relatively poor control-arm PFS (8.2 months) reflects a difficult-to-treat, predominantly double-refractory population, which may amplify the relative treatment effect.,Substantial crossover in the control arm to bispecific antibodies or CAR-T therapies may underestimate the true OS benefit of teclistamab.,Applicability to community oncology settings is uncertain; step-up dosing, CRS monitoring, and infectious risk management (particularly IgG replacement) require infrastructure that may not be uniformly available outside academic or specialized centers.,High-risk cytogenetic subgroups and frail elderly patients are represented, but granular subgroup analyses for the most high-risk populations require full publication review.,Prior BCMA-targeted therapy was an exclusion criterion; results do not inform sequencing after BCMA-directed CAR-T or other bispecific antibodies.,No head-to-head comparison with teclistamab plus daratumumab (as studied in MajesTEC-3); relative benefit of monotherapy vs combination bispecific-based regimens is not established.,Statistical significance is robust, but the clinical importance of the infectious toxicity burden — particularly grade 5 infections at 5.5% — must be weighed in individualized risk-benefit discussions. __BOTTOM_LINE_CATEGORY__ practice_changing __BOTTOM_LINE__ The phase 3 MajesTEC-9 trial demonstrates that teclistamab monotherapy produces a large, statistically robust, and clinically meaningful improvement in both PFS and OS over PVd/Kd in anti-CD38– and lenalidomide-exposed RRMM after 1–3 prior lines, representing the strongest randomized evidence to date supporting BCMA-directed bispecific therapy as early as first relapse. Mateos's editorial contextualizes these findings as a signal to formally redefine the early-relapse treatment paradigm. Adoption should be accompanied by rigorous infectious risk management — including immunoglobulin replacement and antimicrobial prophylaxis — and regulatory approval expansion will be needed before this becomes routine practice in earlier lines.